News
The time is now for physicians to ride the digital disruption wave
CHICAGO – Physicians can shape the outcome of a trend that’s about to explode.
News
Patients frequently drive too soon after ICD implantation
Many patients didn’t recall ever receiving instruction about when to drive again.
Video
Cancer overtakes CVD as cause of death in high-income countries
PARIS – The balance is shifting because cardiovascular deaths are way down in high-resource nations.
News
GALACTIC: Early vasodilation strategy no help in acute heart failure
PARIS – The pragmatic study’s neutral results can inform care of most acute heart failure patients.
News
Bringing focus to the issue: Dr. Elizabeth Loder on gender in medicine
Sexual harassment, hurtful sex-based comments, gender-based barriers to career advancement – and salary – top the list.
News
#MyFirstNameIsDoctor: Why it matters, and what you can do
Putting a name to persistent and insidious gender bias helps address the problem, say female physicians.
News
In patients with CIS, combined omics predicts conversion to clinically definite MS
STOCKHOLM – Oligoclonal band status is helpful for diagnosis, but cannot predict who will go on to develop clinically definite MS.
News
Intensive cognitive training may be needed for memory gains in MS
STOCKHOLM – Patients with MS saw the best results with the most intensive memory strategies.
News
Baseline neurofilament light levels track with brain volume loss in MS
STOCKHOLM – Ten-year data strengthen neurofilament light’s potential prognostic role.
News
Tocilizumab beat azathioprine for NMOSD
STOCKHOLM – The first-ever head-to-head trial compared the two drugs in highly relapsing neuromyelitis optica spectrum disorder.
News
Beyond the lips: Guidance for intraoral procedures
NEW YORK – A gentle hand and good patient education are keys to oral mucosal techniques.
News
Rivaroxaban bests combo therapy in post-PCI AFib
PARIS – Though dosing questions remain, the Japanese AFIRE study affirms current U.S. and European practice.
News
Even with no disease activity, recurrence risk near 50% when stopping DMTs for MS
STOCKHOLM – Younger patients had a significantly higher risk of recurrence when stopping disease modifying therapy.
News
Inebilizumab looks good for neuromyelitis optica in phase 2/3 trial
STOCKHOLM – Attacks were significantly reduced and a marker for tissue damage dropped, but IgG levels will likely have to be tracked long term.
News
In highly active MS, is skipping gadolinium an option?
STOCKHOLM – Though skipping contrast missed a small number of lesions, most patients would still have been classified and treated correctly.